Comparison
Therapeutic ketamine vs psychedelic microdosing
Microdosing psilocybin or LSD has grown popular but lacks robust controlled evidence. Therapeutic ketamine operates at meaningfully different doses, in clinical settings, with stronger short-term data.
Medically reviewed by: Pending medical review(draft)Last updated: June 4, 2026Evidence: Educational synthesis - not medical advice
Therapeutic ketamine
Psychedelic microdosing
Mechanism
Sub-anesthetic ketamine producing measurable glutamate surge and plasticity.
Sub-perceptual doses of classical psychedelics; mechanism in mood regulation unclear.
Evidence
Multiple positive RCTs in TRD, anxiety, PTSD.
Self-report studies dominate; controlled trials mostly fail to separate microdosing from placebo.
Onset
Hours.
Subjective; effects often not clinically replicable.
Duration
Days to weeks per dose.
Variable, often tied to expectation effects.
Side effects
Transient dissociation, BP rise, nausea, monitored setting.
Anxiety, sleep disruption, cardiac concerns with chronic use, legality issues in most jurisdictions.
Access
Licensed clinics.
Illegal in most jurisdictions; unregulated supply.
Best for
Patients seeking evidence-based, supervised treatment.
Currently lacks evidence base to recommend clinically.
Limits
Cost, access.
Weak evidence, legal risk, unknown long-term safety.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.